Incidence and risk of xerosis with targeted anticancer therapies

Background Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. Objective We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2015

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22471

Acceso en línea:

https://doi.org/10.1016/j.jaad.2014.12.010
https://repository.urosario.edu.co/handle/10336/22471

Palabra clave:

Afatinib
Alemtuzumab
Alitretinoin
Anastrozole
Antineoplastic agent
Axitinib
Bevacizumab
Bexarotene
Bortezomib
Bosutinib
Brentuximab vedotin
Cabozantinib
Carfilzomib
Ceritinib
Cetuximab
Crizotinib
Dabrafenib
Daclizumab
Dasatinib
Denileukin diftitox
Denosumab
Erlotinib
Everolimus
Exemestane
Fulvestrant
Gefitinib
Ibritumomab tiuxetan
Ibrutinib
Trastuzumab emtansine
Unindexed drug
Antineoplastic agent
Antineoplastic hormone agonists and antagonists
Enzyme inhibitor
Hormone antagonist
Monoclonal antibody
Tumor protein
Age distribution
Article
Cancer chemotherapy
Cancer patient
Cancer registry
Controlled clinical trial (topic)
Dermatologist
Drug therapy
High risk patient
Human
Incidence
Medical society
Medline
Molecularly targeted therapy
Neoplasm
Phase 1 clinical trial (topic)
Phase 2 clinical trial (topic)
Phase 3 clinical trial (topic)
Priority journal
Randomized controlled trial (topic)
Risk factor
Skin manifestation
Systematic review
Web of science
Xerosis
Adverse effects
Antagonists and inhibitors
Chemically induced
Complication
Meta analysis
Molecularly targeted therapy
Neoplasms
Prospective study
Risk
Severity of illness index
Skin diseases
Antineoplastic agents
Enzyme inhibitors
Hormone antagonists
Humans
Incidence
Molecular targeted therapy
Neoplasm proteins
Neoplasms
Prospective studies
Risk
Severity of illness index
Skin diseases
Cd20
Cd52
Dry skin
Egfr
Hdac
Her2
Incidence
Key words bcr-abl
Mek
Mtor
Raf
Risk
Vegfr
Xerosis
phase ii as topic
phase iii as topic
hormonal
monoclonal
Antibodies
Antineoplastic agents
Clinical trials
Clinical trials

Rights

License

Abierto (Texto Completo)